Combination of thrombolytic and immunosuppressive therapy for coronavirus disease 2019: A case report
In a proportion of patients, severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) causes a multisystem syndrome characterized by hyperinflammation, acute respiratory distress syndrome (ARDS), and hypercoagulability. A 68-year-old man with coronavirus disease 2019 (COVID-19) was admitted to the intensive care unit with respiratory failure, cytokine release syndrome (CRS), and skin ischemia – microthrombosis. Specific coagulation and inflammatory markers (D-dimer, ferritin, and C-reactive protein), along with the clinical picture, triggered the trial of recombinant tissue plasminogen activator (rt-PA) and tocilizumab. This was followed by resolution of the skin ischemia and CRS, while respiratory parameters improved. No major complications associated with rt-PA or tocilizumab occurred. The combination of rt-PA with targeted anti-inflammatory treatment could be a new therapeutic option for patients with COVID-19, ARDS, hyperinflammation, and increased blood viscosity..
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2020 |
|---|---|
| Erschienen: |
2020 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:97 |
|---|---|
| Enthalten in: |
International Journal of Infectious Diseases - 97(2020), Seite 90-93 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Panagiotis Papamichalis [VerfasserIn] |
|---|
| Links: |
doi.org [kostenfrei] |
|---|
| Themen: |
Acute respiratory distress syndrome |
|---|
| doi: |
10.1016/j.ijid.2020.05.118 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
DOAJ010762086 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | DOAJ010762086 | ||
| 003 | DE-627 | ||
| 005 | 20230310031531.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 230225s2020 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1016/j.ijid.2020.05.118 |2 doi | |
| 035 | |a (DE-627)DOAJ010762086 | ||
| 035 | |a (DE-599)DOAJdab0334831ca49cd95e2f67716b6fe1c | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 050 | 0 | |a RC109-216 | |
| 100 | 0 | |a Panagiotis Papamichalis |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Combination of thrombolytic and immunosuppressive therapy for coronavirus disease 2019: A case report |
| 264 | 1 | |c 2020 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a Computermedien |b c |2 rdamedia | ||
| 338 | |a Online-Ressource |b cr |2 rdacarrier | ||
| 520 | |a In a proportion of patients, severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) causes a multisystem syndrome characterized by hyperinflammation, acute respiratory distress syndrome (ARDS), and hypercoagulability. A 68-year-old man with coronavirus disease 2019 (COVID-19) was admitted to the intensive care unit with respiratory failure, cytokine release syndrome (CRS), and skin ischemia – microthrombosis. Specific coagulation and inflammatory markers (D-dimer, ferritin, and C-reactive protein), along with the clinical picture, triggered the trial of recombinant tissue plasminogen activator (rt-PA) and tocilizumab. This was followed by resolution of the skin ischemia and CRS, while respiratory parameters improved. No major complications associated with rt-PA or tocilizumab occurred. The combination of rt-PA with targeted anti-inflammatory treatment could be a new therapeutic option for patients with COVID-19, ARDS, hyperinflammation, and increased blood viscosity. | ||
| 650 | 4 | |a Coronavirus disease 2019 | |
| 650 | 4 | |a Acute respiratory distress syndrome | |
| 650 | 4 | |a Recombinant tissue plasminogen activator | |
| 650 | 4 | |a Tocilizumab | |
| 650 | 4 | |a D-dimer | |
| 653 | 0 | |a Infectious and parasitic diseases | |
| 700 | 0 | |a Antonios Papadogoulas |e verfasserin |4 aut | |
| 700 | 0 | |a Periklis Katsiafylloudis |e verfasserin |4 aut | |
| 700 | 0 | |a Apostolia-Lemonia Skoura |e verfasserin |4 aut | |
| 700 | 0 | |a Michail Papamichalis |e verfasserin |4 aut | |
| 700 | 0 | |a Evangelia Neou |e verfasserin |4 aut | |
| 700 | 0 | |a Dimitrios Papadopoulos |e verfasserin |4 aut | |
| 700 | 0 | |a Spyridon Karagiannis |e verfasserin |4 aut | |
| 700 | 0 | |a Tilemachos Zafeiridis |e verfasserin |4 aut | |
| 700 | 0 | |a Dimitris Babalis |e verfasserin |4 aut | |
| 700 | 0 | |a Apostolos Komnos |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i In |t International Journal of Infectious Diseases |d Elsevier, 2015 |g 97(2020), Seite 90-93 |w (DE-627)DOAJ000043923 |x 18783511 |7 nnns |
| 773 | 1 | 8 | |g volume:97 |g year:2020 |g pages:90-93 |
| 856 | 4 | 0 | |u https://doi.org/10.1016/j.ijid.2020.05.118 |z kostenfrei |
| 856 | 4 | 0 | |u https://doaj.org/article/dab0334831ca49cd95e2f67716b6fe1c |z kostenfrei |
| 856 | 4 | 0 | |u http://www.sciencedirect.com/science/article/pii/S1201971220304252 |z kostenfrei |
| 856 | 4 | 2 | |u https://doaj.org/toc/1201-9712 |y Journal toc |z kostenfrei |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_DOAJ | ||
| 951 | |a AR | ||
| 952 | |d 97 |j 2020 |h 90-93 | ||